Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY and VRTX stocks.

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” ...

Type 1 diabetes concept suggested by insulin syringe] adrian825 Vertex Pharmaceuticals (NASDAQ:VRTX [ has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental therapy for ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

Popular themes on Wall Street today include artificial intelligence (AI), the market for weight management medicines, and the ...

Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management Provided by Business Wire Jun ...

Vertex's candidate, called VX-548, targets NaV1.8 sodium channels, which are thought to play a role in relaying pain signals to the spinal cord from peripheral nerves.

Chronic low back pain (CLBP) is a widespread and long-lasting condition defined by lower back pain that lasts for at least 12 weeks. The l ...

Vertex Pharmaceuticals' leap into the Russell 1000 Index marks its transformation from growth-focused biotech to blue-chip ...